Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

The Prospective Non-randomized Phase II Clinical Trial of Vemurafenib in Combination With Cytarabine and 2-chlorodeoxyadenosine in Children With Langerhans-cell Hisitocytosis With BRAF V600E Mutation

NCT03585686 is registered in ClinicalTrials.gov with Federal Research Institute of Pediatric Hematology, Oncology and Immunology as lead sponsor.

NCT NCT03585686
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03585686 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
The Prospective Non-randomized Phase II Clinical Trial of Vemurafenib in Combination With Cytarabine and 2-chlorodeoxyadenosine in Children With Langerhans-cell Hisitocytosis With BRAF V600E Mutation
Lead sponsor
Federal Research Institute of Pediatric Hematology, Oncology and Immunology
Phase
Phase 2
Overall status
Unknown status
Start date
June 26, 2018
Completion date
December 31, 2023
Enrollment
12 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

langerhans cell histiocytosis